TitleInducible expression of Oct-3/4 reveals synergy with Klf4 in targeting Cyclin A2 to enhance proliferation during early reprogramming.
Publication TypeJournal Article
Year of Publication2022
AuthorsZaveri L, Dhawan J
JournalBiochem Biophys Res Commun
Date Published2022 Jan 08
KeywordsAnimals, Cell Cycle, Cell Differentiation, Cell Proliferation, Cellular Reprogramming, Cyclin A2, Embryo, Mammalian, Fibroblasts, Gene Expression Regulation, Induced Pluripotent Stem Cells, Kruppel-Like Factor 4, Mice, Octamer Transcription Factor-3, Plasmids, Protein Isoforms, Recombinant Fusion Proteins, Signal Transduction, Tamoxifen, Time Factors, Transduction, Genetic

During reprogramming of somatic cells, heightened proliferation is one of the earliest changes observed. While other early events such as mesenchymal-to-epithelial transition have been well studied, the mechanisms by which the cell cycle switches from a slow cycling state to a faster cycling state are still incompletely understood. To investigate the role of Oct-3/4 in this early transition, we created a 4-Hydroxytamoxifen (OHT) dependent Oct-3/4 Estrogen Receptor fusion (OctER). We confirmed that OctER can substitute for Oct-3/4 to reprogram mouse embryonic fibroblasts to a pluripotent state. During the early stages of reprograming, Oct-3/4 and Klf4 individually did not affect cell proliferation but in combination hastened the cell cycle. Using OctER + Klf4, we found that proliferative enhancement is OHT dose-dependent, suggesting that OctER is the driver of this transition. We identified Cyclin A2 as a likely target of Oct-3/4 + Klf4. In mESC, Klf4 and Oct-3/4 bind ∼100bp upstream of Cyclin A2 CCRE, suggesting a potential regulatory role. Using inducible OctER, we show a dose-dependent induction of Cyclin A2 promoter-reporter activity. Taken together, our results suggest that Cyclin A2 is a key early target during reprogramming, and support the view that a rapid cell cycle assists the transition to pluripotency.

Alternate JournalBiochem Biophys Res Commun
PubMed ID34864392